{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T07:57:01Z","timestamp":1789199821377,"version":"build-2803163510"},"reference-count":37,"publisher":"Ovid Technologies (Wolters Kluwer Health)","license":[{"start":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T00:00:00Z","timestamp":1760486400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"abstract":"<jats:p>\n                    Clustered regularly interspaced short palindromic repeats (CRISPR)-based genome editing has expanded from experimental biology to early clinical application, raising the possibility of durable therapies for cardiovascular disease. Because many cardiac conditions are monogenic, they provide clear targets for allele-specific correction or modulation. In hypertrophic cardiomyopathy, preclinical research has shown that base editing of pathogenic\n                    <jats:italic toggle=\"yes\">MYH7<\/jats:italic>\n                    and\n                    <jats:italic toggle=\"yes\">MYBPC3<\/jats:italic>\n                    mutations can restore sarcomere function; concurrently, RNA-targeting approaches selectively suppress mutant transcripts. Dilated cardiomyopathy is more heterogeneous:\n                    <jats:italic toggle=\"yes\">TTN<\/jats:italic>\n                    truncations cause haploinsufficiency that can be offset by CRISPR activation, while\n                    <jats:italic toggle=\"yes\">RBM20<\/jats:italic>\n                    and\n                    <jats:italic toggle=\"yes\">LMNA<\/jats:italic>\n                    mutations require precise correction or interference to restore splicing and nuclear stability. Genome editing is also being tested in familial hypercholesterolemia, where inactivation of\n                    <jats:italic toggle=\"yes\">PCSK9<\/jats:italic>\n                    using lipid nanoparticle\u2013delivered base editors has now advanced to first-in-human trials, achieving sustained LDL-C lowering. Concurrently, efforts targeting\n                    <jats:italic toggle=\"yes\">ANGPTL3<\/jats:italic>\n                    and\n                    <jats:italic toggle=\"yes\">APOB<\/jats:italic>\n                    highlight the prospect of multigene modulation of lipid metabolism. In arrhythmic syndromes, patient-derived cardiomyocytes edited at\n                    <jats:italic toggle=\"yes\">SCN5A<\/jats:italic>\n                    and\n                    <jats:italic toggle=\"yes\">KCNQ1<\/jats:italic>\n                    genes have enabled high-fidelity disease models, while in vivo correction of\n                    <jats:italic toggle=\"yes\">RYR2<\/jats:italic>\n                    in catecholaminergic polymorphic ventricular tachycardia confirms the viability of editing an arrhythmia substrate. In cardiac regeneration, CRISPR activation of developmental transcription factors has enabled direct reprogramming of fibroblasts into cardiomyocyte-like cells within scar tissue. Even with these advances, delivery remains a bottleneck due to immune responses to viral vectors, limitations in the efficiency of lipid nanoparticles in the heart, and the precision required to target cardiomyocytes or conduction cells, all of which slow progress. Future work will depend as much on technical refinement as on navigating ethical, regulatory, and societal concerns.\n                  <\/jats:p>","DOI":"10.1097\/crd.0000000000001087","type":"journal-article","created":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T20:00:21Z","timestamp":1761854421000},"update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":2,"title":["Clustered Regularly Interspaced Short Palindromic Repeats Genome Editing for Cardiovascular Disease: The Future Is Here"],"prefix":"10.1097","author":[{"given":"Nabeel","family":"Sami","sequence":"first","affiliation":[{"name":"Department of Medicine, New York Presbyterian Brooklyn Methodist Hospital, Brooklyn, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manish A.","family":"Parikh","sequence":"additional","affiliation":[{"name":"Department of Medicine, New York Presbyterian Brooklyn Methodist Hospital, Brooklyn, NY"},{"name":"Weill Department of Medicine, Weill Cornell Medicine, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William H.","family":"Frishman","sequence":"additional","affiliation":[{"name":"Department of Medicine, New York Medical College, Valhalla, NY."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen J.","family":"Peterson","sequence":"additional","affiliation":[{"name":"Department of Medicine, New York Presbyterian Brooklyn Methodist Hospital, Brooklyn, NY"},{"name":"Weill Department of Medicine, Weill Cornell Medicine, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2025,10,15]]},"reference":[{"key":"R1-20251030","doi-asserted-by":"crossref","first-page":"qzaf034","DOI":"10.1093\/gpbjnl\/qzaf034","article-title":"CRISPR technology and its emerging applications.","volume":"23","author":"Zhang","year":"2025","journal-title":"Genom Proteom Bioinform"},{"key":"R2-20251030","first-page":"353","article-title":"Mechanism and applications of CRISPR\/Cas-9-mediated genome editing.","volume":"15","author":"Asmamaw","year":"2021","journal-title":"Biologics"},{"key":"R3-20251030","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1126\/science.1225829","article-title":"A programmable dual-RNA\u2013guided DNA endonuclease in adaptive bacterial immunity.","volume":"337","author":"Jinek","year":"2012","journal-title":"Science"},{"key":"R4-20251030","doi-asserted-by":"crossref","first-page":"105","DOI":"10.3349\/ymj.2022.63.2.105","article-title":"Basic principles and clinical applications of CRISPR-based genome editing.","volume":"63","author":"Lim","year":"2022","journal-title":"Yonsei Med J"},{"key":"R5-20251030","doi-asserted-by":"crossref","first-page":"131","DOI":"10.3390\/cells14020131","article-title":"CRISPR-Cas9 in cardiovascular medicine: unlocking new potential for treatment.","volume":"14","author":"Bonowicz","year":"2025","journal-title":"Cells"},{"key":"R6-20251030","doi-asserted-by":"crossref","first-page":"1258096","DOI":"10.1126\/science.1258096","article-title":"The new frontier of genome engineering with CRISPR-Cas9.","volume":"346","author":"Doudna","year":"2014","journal-title":"Science"},{"key":"R7-20251030","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1038\/s41591-022-02176-5","article-title":"Base editing correction of hypertrophic cardiomyopathy in human cardiomyocytes and humanized mice.","volume":"29","author":"Chai","year":"2023","journal-title":"Nat Med"},{"key":"R8-20251030","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1038\/s41591-022-02184-5","article-title":"CRISPR gene-editing therapies for hypertrophic cardiomyopathy.","volume":"29","author":"Strong","year":"2023","journal-title":"Nat Med"},{"key":"R9-20251030","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1038\/s41422-024-00930-7","article-title":"Base editing effectively prevents early-onset severe cardiomyopathy in Mybpc3 mutant mice.","volume":"34","author":"Wu","year":"2024","journal-title":"Cell Res"},{"key":"R10-20251030","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1161\/CIRCULATIONAHA.123.067890","article-title":"Allele-specific suppression of variant MYH7 with high-precision RNA nuclease CRISPR-Cas13d prevents hypertrophic cardiomyopathy.","volume":"150","author":"Yang","year":"2024","journal-title":"Circulation"},{"key":"R11-20251030","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1161\/CIRCULATIONAHA.123.063972","article-title":"CRISPR activation reverses haploinsufficiency and functional deficits caused by TTN truncation variants.","volume":"149","author":"Ghahremani","year":"2024","journal-title":"Circulation"},{"key":"R12-20251030","doi-asserted-by":"crossref","first-page":"eade1633","DOI":"10.1126\/scitranslmed.ade1633","article-title":"Precise genomic editing of pathogenic mutations in RBM20 rescues dilated cardiomyopathy.","volume":"14","author":"Nishiyama","year":"2022","journal-title":"Sci Transl Med"},{"key":"R13-20251030","doi-asserted-by":"crossref","first-page":"3714","DOI":"10.1038\/s41467-023-39352-1","article-title":"Striated muscle-specific base editing enables correction of mutations causing dilated cardiomyopathy.","volume":"14","author":"Grosch","year":"2023","journal-title":"Nat Commun"},{"key":"R14-20251030","doi-asserted-by":"crossref","first-page":"7000","DOI":"10.1038\/s41467-024-51318-5","article-title":"Lamin A\/C deficiency-mediated ROS elevation contributes to pathogenic phenotypes of dilated cardiomyopathy in iPSC model.","volume":"15","author":"Qiu","year":"2024","journal-title":"Nat Commun"},{"key":"R15-20251030","first-page":"e79372","article-title":"The future of CRISPR-Cas9 gene therapy in cardiomyopathies: a review of its therapeutic potential and emerging applications.","volume":"17","author":"Moradi","year":"2025","journal-title":"Cureus"},{"key":"R16-20251030","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1038\/s41587-022-01445-5","article-title":"Verve takes base editors into humans.","volume":"40","author":"Mullard","year":"2022","journal-title":"Nat Biotechnol"},{"key":"R17-20251030","doi-asserted-by":"crossref","first-page":"2466","DOI":"10.3390\/cells12202466","article-title":"Development of new genome editing tools for the treatment of hyperlipidemia.","volume":"12","author":"Preta","year":"2023","journal-title":"Cells"},{"key":"R18-20251030","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1161\/CIRCULATIONAHA.122.062132","article-title":"Efficacy and safety of an investigational single-course CRISPR base-editing therapy targeting PCSK9 in nonhuman primate and mouse models.","volume":"147","author":"Lee","year":"2023","journal-title":"Circulation"},{"key":"R19-20251030","article-title":"VERVE 101: CRISPR-based gene editing therapy shows promise in lowering LDL-C and PCSK9 in HeFH patients.","author":"Bellinger","year":"2023","journal-title":"ACC News"},{"key":"R20-20251030","article-title":"Experimental treatment called VERVE-102 edits DNA to lower LDL cholesterol.","author":"Lanese","year":"2025","journal-title":"Live Science"},{"key":"R21-20251030","doi-asserted-by":"crossref","first-page":"2774","DOI":"10.1007\/s12015-023-10602-5","article-title":"Using ribonucleoprotein-based CRISPR\/Cas9 to edit single nucleotide on human induced pluripotent stem cells to model type 3 long QT syndrome (SCN5A\u00b1).","volume":"19","author":"Ge","year":"2023","journal-title":"Stem Cell Rev Rep"},{"key":"R22-20251030","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1186\/s13287-022-02964-3","article-title":"KCNQ1-deficient and KCNQ1-mutant human embryonic stem cell-derived cardiomyocytes for modeling QT prolongation.","volume":"13","author":"Song","year":"2022","journal-title":"Stem Cell Res Ther"},{"key":"R23-20251030","doi-asserted-by":"crossref","first-page":"8","DOI":"10.20517\/jca.2023.42","article-title":"Long-term efficacy and safety of cardiac genome editing for catecholaminergic polymorphic ventricular tachycardia.","volume":"4","author":"Moore","year":"2024","journal-title":"J Cardiovasc Aging"},{"key":"R24-20251030","doi-asserted-by":"crossref","first-page":"e024410","DOI":"10.1161\/JAHA.121.024410","article-title":"Brugada syndrome: different experimental models and the role of human cardiomyocytes from induced pluripotent stem cells.","volume":"11","author":"Li","year":"2022","journal-title":"J Am Heart Assoc"},{"key":"R25-20251030","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.yjmcc.2023.03.009","article-title":"Cellular reprogramming of fibroblasts in heart regeneration.","volume":"180","author":"Chi","year":"2023","journal-title":"J Mol Cell Cardiol"},{"key":"R26-20251030","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.jacbts.2023.06.012","article-title":"Fibroblast reprogramming in cardiac repair.","volume":"9","author":"Wang","year":"2024","journal-title":"JACC Basic Transl Sci"},{"key":"R27-20251030","doi-asserted-by":"crossref","first-page":"102390","DOI":"10.1016\/j.omtn.2024.102390","article-title":"Direct cardiac reprogramming via combined CRISPRa-mediated endogenous Gata4 activation and exogenous Mef2c and Tbx5 expression.","volume":"35","author":"Huang","year":"2024","journal-title":"Mol Ther Nucleic Acids"},{"key":"R28-20251030","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.ymthe.2021.10.015","article-title":"CRISPR activation of endogenous genes reprograms fibroblasts into cardiovascular progenitor cells for myocardial infarction therapy.","volume":"30","author":"Jiang","year":"2022","journal-title":"Mol Ther"},{"key":"R29-20251030","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1097\/HCO.0000000000000386","article-title":"Cardiac gene therapy with adeno-associated virus-based vectors.","volume":"32","author":"Chamberlain","year":"2017","journal-title":"Curr Opin Cardiol"},{"key":"R30-20251030","doi-asserted-by":"crossref","first-page":"15348","DOI":"10.1038\/s41598-020-72216-y","article-title":"Adeno-associated virus-mediated gene delivery promotes S-phase entry-independent precise targeted integration in cardiomyocytes.","volume":"10","author":"Kohama","year":"2020","journal-title":"Sci Rep"},{"key":"R31-20251030","doi-asserted-by":"crossref","first-page":"675897","DOI":"10.3389\/fimmu.2021.675897","article-title":"Challenges posed by immune responses to AAV vectors: addressing root causes.","volume":"12","author":"Hamilton","year":"2021","journal-title":"Front Immunol"},{"key":"R32-20251030","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1182\/blood-2013-01-306647","article-title":"Immune responses to AAV vectors: overcoming barriers to successful gene therapy.","volume":"122","author":"Mingozzi","year":"2013","journal-title":"Blood"},{"key":"R33-20251030","first-page":"e471","article-title":"Gene therapy in cardiovascular disease: recent advances and future directions in science: a science advisory from the American Heart Association.","volume":"150","author":"Kim","year":"2024","journal-title":"Circulation"},{"key":"R34-20251030","doi-asserted-by":"crossref","first-page":"100517","DOI":"10.1016\/j.cobme.2023.100517","article-title":"AAV-based CRISPR-Cas9 genome editing: challenges and engineering opportunities.","volume":"29","author":"Kabadi","year":"2024","journal-title":"Curr Opin Biomed Eng"},{"key":"R35-20251030","doi-asserted-by":"crossref","first-page":"8960236","DOI":"10.1155\/2017\/8960236","article-title":"The impact of CRISPR\/Cas9 technology on cardiac research: from disease modelling to therapeutic approaches.","volume":"2017","author":"Motta","year":"2017","journal-title":"Stem Cells Int"},{"key":"R36-20251030","doi-asserted-by":"crossref","first-page":"e944204","DOI":"10.12659\/MSM.944204","article-title":"First regulatory approvals for CRISPR-Cas9 therapeutic gene editing for sickle cell disease and transfusion-dependent \u03b2-thalassemia.","volume":"30","author":"Parums","year":"2024","journal-title":"Med Sci Monit"},{"key":"R37-20251030","doi-asserted-by":"crossref","first-page":"874","DOI":"10.2105\/AJPH.2023.307315","article-title":"CRISPR in public health: the health equity implications and role of community in gene-editing research and applications.","volume":"113","author":"Subica","year":"2023","journal-title":"Am J Public Health"}],"container-title":["Cardiology in Review"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/CRD.0000000000001087","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T20:00:25Z","timestamp":1761854425000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/CRD.0000000000001087"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,15]]},"references-count":37,"URL":"https:\/\/doi.org\/10.1097\/crd.0000000000001087","relation":{},"ISSN":["1538-4683"],"issn-type":[{"value":"1538-4683","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,15]]}}}